Subtype
Ovarian Carcinoma
CI-CAN-00003517Explore in graph →
270 active trials2 approved drugs24 evidence items
- NCIt
- C4908
- DOID
- 2152
- DOID
- 4001
- MeSH
- D000077216
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003517Explore in graph →
Clinical trials
895 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (145)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05215496 | [18F]Fluoro-PEG-folate PET/CT Imaging in Epithelial Ovarian Cancer | terminated | Phase 1 | 5 | Lioe-Fee de Geus-Oei, MD PhDOTHER | 1 | Mar 15, 2024 | clinicaltrials |
| NCT02923739 | Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | terminated | Phase 2 | 9 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 13, 2024 | clinicaltrials |
| NCT04718376 | A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Relapsed Ovarian Cancer | terminated | Phase 1 | 56 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Mar 7, 2024 | clinicaltrials |
| NCT03606486 | Lavage of the Uterine Cavity for Diagnosis of Ovarian Cancer | terminated | N/A | 52 | University of WashingtonOTHER | 1 | Jan 17, 2024 | clinicaltrials |
| NCT04999605 | A Study of AK112 Combined With PARP Inhibitor in the Treatment of Recurrent Ovarian Cancer | terminated | Phase 1 / Phase 2 | 8 | AkesoINDUSTRY | 1 | Jan 5, 2024 | clinicaltrials |
| NCT03861403 | A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors | terminated | Phase 1 | 10 | Leap Therapeutics, Inc.INDUSTRY | 1 | Nov 30, 2023 | clinicaltrials |
| NCT03641287 | The Effects of Exercise on Distress, Quality of Life, and Biomarkers in Ovarian Cancer Survivors | terminated | N/A | 64 | University of WashingtonOTHER | 1 | Nov 29, 2023 | clinicaltrials |
| NCT03412630 | Perfusion CT in Predicting Outcomes in Ovarian, Fallopian, or Peritoneal Cancer With Bevacizumab | terminated | N/A | 1 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Nov 24, 2023 | clinicaltrials |
| NCT02834975 | Pembrolizumab, Paclitaxel, and Carboplatin in Patients With Advanced Stage Epithelial Ovarian Cancer (EOC). | terminated | Phase 2 | 26 | University of MiamiOTHER | 1 | Nov 7, 2023 | clinicaltrials |
| NCT01849874 | A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer | terminated | Phase 3 | 341 | PfizerINDUSTRY | 19 | Oct 30, 2023 | clinicaltrials |
| NCT04729608 | Batiraxcept (AVB-S6-500)/Placebo in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer(AXLerate-OC) | terminated | Phase 3 | 366 | Aravive, Inc.INDUSTRY | 11 | Oct 30, 2023 | clinicaltrials |
| NCT05329545 | Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT)(UP-NEXT) | terminated | Phase 3 | 20 | Mersana TherapeuticsINDUSTRY | 3 | Oct 26, 2023 | clinicaltrials |
| NCT04907968 | Study of Upifitamab Rilsodotin in Combination With Carboplatin in Participants With High-grade Serous Ovarian Cancer(UPGRADE) | terminated | Phase 1 | 31 | Mersana TherapeuticsINDUSTRY | 1 | Oct 10, 2023 | clinicaltrials |
| NCT00968799 | Hyperthermic Intraoperative Intraperitoneal Chemotherapy of Recurrent Ovarian Cancer - A Feasibility Study | terminated | N/A | 6 | Cantonal Hospital of St. GallenOTHER | 1 | Aug 8, 2023 | clinicaltrials |
| NCT02059265 | Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer | terminated | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | Aug 1, 2023 | clinicaltrials |
| NCT03824704 | A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES) | terminated | Phase 2 | 1 | pharmaand GmbHINDUSTRY | 1 | Jun 12, 2023 | clinicaltrials |
| NCT03933813 | Evaluation and Treatment of Iron Deficiency in Ovarian Cancer Patients | terminated | Phase 1 / Phase 2 | 9 | University of Wisconsin, MadisonOTHER | 1 | Jan 5, 2023 | clinicaltrials |
| NCT04851834 | NTX-301 Monotherapy in Advanced Solid Tumours and in Combination With Platinum-based Chemotherapy in Advanced Ovarian & Bladder Cancer and in Combination With Temozolomide in High-grade Glioma | terminated | Phase 1 / Phase 2 | 12 | Xennials Therapeutics Australia Pty LtdINDUSTRY | 1 | Dec 20, 2022 | clinicaltrials |
| NCT02978222 | Folate Receptor Alpha Peptide Vaccine With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovarian Cancer | terminated | Phase 2 | 120 | Marker Therapeutics, Inc.INDUSTRY | 1 | Dec 15, 2022 | clinicaltrials |
| NCT04562298 | A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-M23, a CAR-T Cell Therapy Targeting MSLN in Patients With Relapsed and Refractory Epithelial Ovarian Cancer | terminated | Phase 1 | 15 | Shanghai East HospitalOTHER | 1 | Aug 18, 2022 | clinicaltrials |
| NCT03382574 | Pilot Study of Denosumab in BRCA1/2 Mutation Carriers Scheduled for Risk-Reducing Salpingo-Oophorectomy | terminated | Early Phase 1 | 2 | National Cancer Institute (NCI)NIH | 2 | Jun 14, 2022 | clinicaltrials |
| NCT03100006 | Phase Ib/IIa Trial to Evaluate Oregovomab and Nivolumab in Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin(ORION-01) | terminated | Phase 1 / Phase 2 | 13 | National Cancer Centre, SingaporeOTHER | 1 | Jun 13, 2022 | clinicaltrials |
| NCT02900560 | Study of Pembrolizumab With or Without CC-486 in Patients With Platinum-resistant Ovarian Cancer | terminated | Phase 2 | 34 | Translational Research in OncologyOTHER | 1 | Jun 10, 2022 | clinicaltrials |
| NCT03924245 | Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers | terminated | Phase 1 | 3 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Apr 4, 2022 | clinicaltrials |
| NCT03690739 | Evaluation of Symptom Benefit Rate of Trabectedin/PLD in Patients With Recurrent Ovarian Cancer | terminated | Phase 3 | 9 | AGO Research GmbHINDUSTRY | 1 | Feb 24, 2022 | clinicaltrials |
| NCT01018563 | An Open Label Extension Study of the Efficacy of MORAb-003 | terminated | Phase 2 | 3 | MorphotekINDUSTRY | 2 | Dec 8, 2021 | clinicaltrials |
| NCT03608618 | Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for Treatment of Advanced Ovarian Cancer and Peritoneal Mesothelioma | terminated | Phase 1 | 14 | MaxCyte, Inc.INDUSTRY | 1 | Sep 5, 2021 | clinicaltrials |
| NCT03029585 | Phase II Study of Intraperitoneal NanoPac® in Patients With Ovarian Cancer | terminated | Phase 2 | 10 | NanOlogy, LLCINDUSTRY | 1 | Apr 27, 2021 | clinicaltrials |
| NCT01334047 | Trial of Vaccine Therapy in Recurrent Platinum Sensitive Ovarian Cancer Patients | terminated | Phase 1 / Phase 2 | 5 | Steinar AamdalOTHER | 1 | Feb 26, 2021 | clinicaltrials |
| NCT02947152 | HKT288 in Solid Tumors, Including Epithelial Ovarian Cancer and Renal Cell Carcinoma | terminated | Phase 1 | 9 | Novartis PharmaceuticalsINDUSTRY | 6 | Dec 8, 2020 | clinicaltrials |
| NCT03957096 | A Safety Study of SGN-CD47M in Patients With Solid Tumors | terminated | Phase 1 | 16 | Seagen Inc.INDUSTRY | 1 | Sep 17, 2020 | clinicaltrials |
| NCT01249443 | Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection | terminated | Phase 1 | 17 | AIDS Malignancy ConsortiumNETWORK | 1 | Jul 29, 2020 | clinicaltrials |
| NCT01312376 | Autologous T-Cells Combined With Autologous OC-DC Vaccine in Ovarian Cancer | terminated | Phase 1 | 18 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Apr 24, 2020 | clinicaltrials |
| NCT02012192 | GANNET53: Ganetespib in Metastatic, p53-mutant, Platinum-resistant Ovarian Cancer | terminated | Phase 1 / Phase 2 | 133 | Medical University InnsbruckOTHER | 4 | Aug 13, 2019 | clinicaltrials |
| NCT01159067 | Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload | terminated | Phase 2 | 1 | City of Hope Medical CenterOTHER | 1 | Jun 18, 2019 | clinicaltrials |
| NCT02943317 | Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Defactinib in Combination With Avelumab in Epithelial Ovarian Cancer | terminated | Phase 1 | 98 | Verastem, Inc.INDUSTRY | 1 | Apr 30, 2019 | clinicaltrials |
| NCT02575807 | Safety and Efficacy of CRS-207 With Epacadostat in Platinum Resistant Ovarian, Fallopian or Peritoneal Cancer(SEASCAPE) | terminated | Phase 1 / Phase 2 | 35 | Aduro Biotech, Inc.INDUSTRY | 2 | Apr 4, 2019 | clinicaltrials |
| NCT00039091 | Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer, Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Non-Small Cell Lung Cancer | terminated | Phase 1 | 26 | National Cancer Institute (NCI)NIH | 1 | Sep 5, 2018 | clinicaltrials |
| NCT00899093 | YKL-40 in Serum Samples From Patients With Newly Diagnosed Stage III-IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Receiving Chemotherapy | terminated | — | 2,500 | Gynecologic Oncology GroupNETWORK | 1 | May 22, 2018 | clinicaltrials |
| NCT01275664 | Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian Cancer | terminated | N/A | 4 | Gynecologic Oncology GroupNETWORK | 1 | May 22, 2018 | clinicaltrials |
| NCT02412124 | Peer-to-Peer Support Program in Improving Quality of Life Outcomes in Patients With Gynecologic Cancer and Their Caregivers | terminated | N/A | 3 | City of Hope Medical CenterOTHER | 1 | May 11, 2018 | clinicaltrials |
| NCT01773889 | A Trial of Intravenous Denileukin Diftitox Plus Subcutaneous Pegylated IFNα-2A in Stage III or IV Ovarian Cancer | terminated | Phase 2 | 2 | The University of Texas Health Science Center at San AntonioOTHER | 1 | Apr 10, 2018 | clinicaltrials |
| NCT02708511 | Copper Cu 64-DOTA-B-Fab PET/CT in Imaging Patients With Ovarian and Breast Cancer | terminated | Phase 1 | 2 | Sanjiv Sam GambhirOTHER | 1 | Apr 5, 2018 | clinicaltrials |
| NCT01936974 | (PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma(PGA) | terminated | Phase 2 | 7 | Western Regional Medical CenterOTHER | 1 | Feb 20, 2018 | clinicaltrials |
| NCT00004221 | Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III Ovarian Cancer | terminated | Phase 2 | 12 | Gynecologic Oncology GroupNETWORK | 1 | Aug 9, 2017 | clinicaltrials |
| NCT01681368 | Birinapant for Advanced Ovarian, Fallopian Tube, and Peritoneal Cancer | terminated | Phase 2 | 11 | National Cancer Institute (NCI)NIH | 1 | May 30, 2017 | clinicaltrials |
| NCT01494012 | Phase I Stereotactic Body Radiation for Metastatic or Recurrent Platinum-Resistant Ovarian Cancer | terminated | Phase 1 | 1 | Stanford UniversityOTHER | 1 | Apr 28, 2017 | clinicaltrials |
| NCT02218502 | Study Into a New Diagnostic Tool (Simple Ultrasound-based Rules) in Patients With Adnexal Masses(SUBSONiC) | terminated | N/A | 50 | Maastricht University Medical CenterOTHER | 1 | Mar 28, 2017 | clinicaltrials |
| NCT01521143 | Cvac as Maintenance Treatment in Patients With Epithelial Ovarian Cancer in Complete Remission Following First-line Chemotherapy or Second-line Treatment(CANVAS) | terminated | Phase 2 | 91 | Prima BioMed LtdINDUSTRY | 2 | Dec 14, 2016 | clinicaltrials |
| NCT02035345 | Slowed Carboplatin Infusion for Ovarian Cancer Patients Receiving Carboplatin Re-Treatment | terminated | Phase 4 | 15 | Massachusetts General HospitalOTHER | 1 | Dec 8, 2016 | clinicaltrials |
Data updated 22 days agoSource updated Mar 15, 2024source: clinicaltrials